First National Bank of Omaha Makes New $8.85 Million Investment in Zoetis Inc. $ZTS

First National Bank of Omaha bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 60,469 shares of the company’s stock, valued at approximately $8,848,000.

A number of other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Zoetis by 1.0% in the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock worth $6,190,326,000 after buying an additional 419,777 shares in the last quarter. Geode Capital Management LLC raised its position in Zoetis by 0.9% during the second quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after purchasing an additional 95,294 shares in the last quarter. Norges Bank bought a new stake in Zoetis in the 2nd quarter worth approximately $809,491,000. Brown Advisory Inc. boosted its stake in shares of Zoetis by 5.7% in the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock valued at $726,629,000 after purchasing an additional 250,829 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Zoetis by 113.0% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after buying an additional 1,995,491 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 0.9%

ZTS stock opened at $125.45 on Wednesday. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.00. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The firm has a market cap of $52.96 billion, a PE ratio of 20.84, a P/E/G ratio of 2.12 and a beta of 0.96. The firm’s fifty day moving average is $124.79 and its 200 day moving average is $135.06.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. Zoetis’s payout ratio is presently 35.22%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ZTS shares. JPMorgan Chase & Co. dropped their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Barclays assumed coverage on shares of Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target for the company. Morgan Stanley set a $160.00 price target on Zoetis in a report on Thursday, December 18th. Stifel Nicolaus decreased their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Finally, BTIG Research restated a “buy” rating and set a $160.00 price target on shares of Zoetis in a research note on Wednesday, December 3rd. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.